Search results for "Cell transplantation"

showing 10 items of 493 documents

Relationships of growth factors, proinflammatory cytokines, and anti-inflammatory cytokines with long-term clinical results of autologous bone marrow…

2017

Aim The aim of the study was to test the hypothesis suggesting that the pre-intervention levels of proinflammatory cytokines, anti-inflammatory cytokines, and angiogenic growth factors predict the long-term clinical results of autologous bone marrow-derived mononuclear cell (ABMMC) transplantation in patients with primary ST elevation myocardial infarction (STEMI). Methods and results From 2003 to 2006, a total of 62 patients with primary STEMI were enrolled in an open randomized study registered under the title ESTABOMA. Patients were randomized into two groups: group 1 included patients treated with percutaneous coronary intervention (PCI) and ABMMC transplantation (n = 28); group 2 compr…

Male0301 basic medicinePhysiologyCardiovascular ProceduresCell Transplantationmedicine.medical_treatmentMyocardial InfarctionSocial Scienceslcsh:Medicine030204 cardiovascular system & hematologyPathology and Laboratory MedicineVascular MedicineGastroenterologyAnginaEndocrinology0302 clinical medicineImmune PhysiologyMedicine and Health SciencesBlood and Lymphatic System ProceduresPsychologyMyocardial infarctionlcsh:ScienceImmune ResponseBone Marrow TransplantationInnate Immune SystemMultidisciplinaryCardiac TransplantationAnginaMiddle AgedBrain natriuretic peptidesurgical procedures operativeCytokinesIntercellular Signaling Peptides and ProteinsFemaleInflammation MediatorsResearch Articlemedicine.medical_specialtySocial PsychologyImmunologyCardiologySurgical and Invasive Medical ProceduresTransplantation AutologousProinflammatory cytokine03 medical and health sciencesSigns and SymptomsDiagnostic MedicineGrowth FactorsInternal medicineчрескожное коронарное вмешательствоmedicineHumanscardiovascular diseasesInflammationTransplantationEndocrine Physiologybusiness.industrylcsh:RBiology and Life SciencesPercutaneous coronary interventionOrgan TransplantationMolecular Developmentmedicine.diseaseпровоспалительные цитокиныинфаркт миокардаTransplantation030104 developmental biologyImmune SystemHeart failureImmunologyConventional PCIтрансплантация мононуклеарных клетокlcsh:Qbusinessаутологичная трансплантация костного мозгаDevelopmental BiologyStem Cell Transplantation
researchProduct

The kinetics of torque teno virus plasma DNA load shortly after engraftment predicts the risk of high-level CMV DNAemia in allogeneic hematopoietic s…

2018

Monitoring Torque teno virus (TTV) DNA load helps to estimate the risk of opportunistic infections in solid organ transplant recipients. We investigated whether the early kinetic pattern of plasma TTV DNA load after allogeneic hematopoietic stem cell transplantation (allo-HSCT) associates with subsequent CMV and EBV DNAemia. This study included 71 allo-HSCT patients. We found that the area under the curve (AUC) for log10 TTV DNA loads quantified by days 20 and 30 after transplantation (TTV DNA load AUC20-30), was significantly lower (P=0.036) in patients who subsequently developed CMV DNAemia requiring preemptive antiviral therapy (n=17) than in those who did not (n=8) or had no CMV DNAemia…

Male0301 basic medicineTorque teno virusTransplantation Conditioningmedicine.medical_treatment030106 microbiologyHematopoietic stem cell transplantation03 medical and health sciencesInterferonmedicineHumansRetrospective StudiesTorque teno virusTransplantationbusiness.industryHematopoietic Stem Cell TransplantationArea under the curvevirus diseasesHematologyCmv dnaemiaVirologyTransplantation030104 developmental biologyHematology; TransplantationCytomegalovirus InfectionsDNA ViralImmunologyFemaleTransplantation ConditioningbusinessCD8medicine.drugBone Marrow Transplantation
researchProduct

Translating intracarotid artery transplantation of bone marrow-derived NCS-01 cells for ischemic stroke: Behavioral and histological readouts and mec…

2019

Abstract The present study used in vitro and in vivo stroke models to demonstrate the safety, efficacy, and mechanism of action of adult human bone marrow‐derived NCS‐01 cells. Coculture with NCS‐01 cells protected primary rat cortical cells or human neural progenitor cells from oxygen glucose deprivation. Adult rats that were subjected to middle cerebral artery occlusion, transiently or permanently, and subsequently received intracarotid artery or intravenous transplants of NCS‐01 cells displayed dose‐dependent improvements in motor and neurological behaviors, and reductions in infarct area and peri‐infarct cell loss, much better than intravenous administration. The optimal dose was 7.5 × …

Male0301 basic medicinecell lofunctional recoverymedicine.medical_treatmentBasic fibroblast growth factorCell- and Tissue-Based TherapyPharmacologycerebral ischemia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBone Marrowmental disordersmedicinecytokineAnimalsHumansinfarctcell losslcsh:QH573-671cell transplantationStrokeIschemic Strokelcsh:R5-920business.industrylcsh:CytologyMesenchymal stem cellCell BiologyGeneral MedicineStem-cell therapymedicine.diseaseNeural stem cellcytokinesRatsTransplantation030104 developmental biologymedicine.anatomical_structurechemistrymotor deficitsEnabling Technologies for Cell‐based Clinical TranslationBone marrowStem cellbusinesslcsh:Medicine (General)030217 neurology & neurosurgeryStem Cell TransplantationDevelopmental Biology
researchProduct

Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality fr…

2018

Abstract Risk factors (RFs) and mortality data of community‐acquired respiratory virus (CARVs) lower respiratory tract disease (LRTD) with concurrent pulmonary co‐infections in the setting of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is scarce. From January 2011 to December 2017, we retrospectively compared the outcome of allo‐HSCT recipients diagnosed of CARVs LRTD mono‐infection (n = 52, group 1), to those with viral, bacterial, or fungal pulmonary CARVs LRTD co‐infections (n = 15, group 2; n = 20, group 3, and n = 11, group 4, respectively), and with those having bacterial pneumonia mono‐infection (n = 19, group 5). Overall survival (OS) at day 60 after bronchoalveol…

Male0301 basic medicinemedicine.medical_treatmentcommunity acquired respiratory virusHematopoietic stem cell transplantationBronchoalveolar LavageGastroenterology0302 clinical medicineRisk Factorsrespiratory virus co‐infectionsLungRespiratory Tract Infectionsmedicine.diagnostic_testRespiratory tract infectionsCoinfectionHematopoietic Stem Cell TransplantationMiddle AgedCommunity-Acquired InfectionsInfectious Diseasesmedicine.anatomical_structureVirusesvirus-bacterial mixed infectionsRespiratory virusFemaleOriginal Articlerespiratory virus co-infectionsBronchoalveolar Lavage FluidAdultmedicine.medical_specialtyvirus‐bacterial mixed infections030106 microbiologyContext (language use)CMV DNAemiaAntiviral Agents03 medical and health sciencesInternal medicinemedicineHumansTransplantation Homologousallogeneic hematopoietic stem cell transplantationAgedRetrospective StudiesTransplantationLungBacteriabusiness.industryFungiBacterial pneumoniaOriginal Articlesmedicine.diseaseTransplantationBronchoalveolar lavagebusinessimmunodeficiency score index030215 immunology
researchProduct

Treatment of COVID-19 with MSCs: how does it work?

2021

The infusion of coronavirus disease 2019 (COVID-19) patients with mesenchymal stem cells (MSCs) potentially improves clinical symptoms, but the underlying mechanism remains unclear. We conducted a randomized, single-blind, placebo-controlled (29 patients/group) phase II clinical trial to validate previous findings and explore the potential mechanisms. Patients treated with umbilical cord-derived MSCs exhibited a shorter hospital stay (P = 0.0198) and less time required for symptoms remission (P = 0.0194) than those who received placebo. Based on chest images, both severe and critical patients treated with MSCs showed improvement by day 7 (P = 0.0099) and day 21 (P = 0.0084). MSC-treated pat…

Male2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)T-LymphocytesB-Lymphocyte SubsetsAntibodies ViralMesenchymal Stem Cell TransplantationExtracellular TrapsGeneral Biochemistry Genetics and Molecular BiologyArticleImmunomodulationMiceMedicineAnimalsHumansGeneral Environmental ScienceAgedVenous Thrombosisbusiness.industrySARS-CoV-2Mesenchymal stem cellCOVID-19Middle AgedVirologyResearch HighlightMice Inbred C57BLCytoskeletal ProteinsDisease Models AnimalMechanisms of diseaseC-Reactive ProteinWork (electrical)Leukocytes MononuclearMesenchymal stem cellsCytokinesFemaleGeneral Agricultural and Biological SciencesbusinessScience China. Life Sciences
researchProduct

Therapeutic effects of hMAPC and hMSC transplantation after stroke in mice.

2012

Stroke represents an attractive target for stem cell therapy. Although different types of cells have been employed in animal models, a direct comparison between cell sources has not been performed. The aim of our study was to assess the effect of human multipotent adult progenitor cells (hMAPCs) and human mesenchymal stem cells (hMSCs) on endogenous neurogenesis, angiogenesis and inflammation following stroke. BALB/Ca-RAG 2(-/-) γC(-/-) mice subjected to FeCl(3) thrombosis mediated stroke were intracranially injected with 2 × 10(5) hMAPCs or hMSCs 2 days after stroke and followed for up to 28 days. We could not detect long-term engraftment of either cell population. However, in comparison w…

MaleAnatomy and PhysiologyMousemedicine.medical_treatmentCell therapyMiceCell MovementMolecular Cell BiologyNeurobiology of Disease and RegenerationMedicineMultidisciplinaryNeuronal MorphologyNeurogenesisQRBrainInfarction Middle Cerebral ArteryAnimal ModelsStem-cell therapyStrokeAdult Stem Cellsmedicine.anatomical_structureNeurologyMedicineResearch ArticleAdult stem cellCell PhysiologyHistologyCell SurvivalCerebrovascular DiseasesScienceTherapeutic effectsNeurophysiologyNeovascularization PhysiologicSubventricular zoneMesenchymal Stem Cell TransplantationNeurological SystemModel OrganismsAnimalsHumansProgenitor cellBiologyTransplantationbusiness.industryMultipotent Stem CellsMesenchymal stem cellMultipotent Stem CellCellular NeuroscienceImmunologyCancer researchMolecular NeurosciencebusinesshMAPC and hMSCNeurosciencePLoS ONE
researchProduct

Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving or…

2015

Studies that analyze the epidemiology and risk factors for invasive fungal disease (IFD) after engraftment in alloSCT are few in number. This single-center retrospective study included 404 alloSCT adult recipients surviving > 40 days who engrafted and were discharged without prior IFD. All patients who received >= 20 mg/day of prednisone were assigned to primary oral prophylaxis (itraconazole or low-dose voriconazole). The primary end point was the cumulative incidence (CI) of probable/proven IFD using the European Organization for Research and Treatment of Cancer and Mycoses Study Group (EORTC/MSG) criteria. The independent prognostic factors after multivariate analyses were used to constr…

MaleAntifungal AgentsTransplantation ConditioningPremedicationmedicine.medical_treatmentMULTICENTERAdministration OralHematopoietic stem cell transplantationEchinocandinsCOMPETING RISKCaspofunginRisk FactorsCause of DeathINFECTIONGranulocyte Colony-Stimulating FactorEPIDEMIOLOGYCumulative incidenceTreatment FailureFramingham Risk ScoreIncidenceIncidence (epidemiology)Hematopoietic Stem Cell TransplantationHematologyMiddle AgedAllograftsHematologic NeoplasmsVORICONAZOLEDrug Therapy CombinationFemaleASPERGILLOSISRisk assessmentFungemiamedicine.drugAdultmedicine.medical_specialtyNeutropeniaANTIFUNGAL PROPHYLAXISNeutropeniaRisk AssessmentITRACONAZOLEMedication AdherenceImmunocompromised HostLipopeptidesYoung AdultAmphotericin BInternal medicinemedicineAspergillosisHumansAgedRetrospective StudiesVoriconazoleTransplantationbusiness.industryRetrospective cohort studyFLUCONAZOLETriazolesmedicine.diseaseSurvival AnalysisSurgeryMycosesPatient CompliancebusinessSCT
researchProduct

Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis

2006

Background: Micafungin (FK463) is a new lipopeptide compound (echinocandin) with activity against Aspergillus and Candida species. This study evaluated the safety and efficacy of micafungin in patients with proven or probable invasive aspergillosis (IA). Methods: A multinational, non-comparative study was conducted to examine proven or probable (pulmonary only) Aspergillus species infection in a wide variety of patient populations. The study employed an open-label design utilizing micafungin alone or in combination with another systemic antifungal agent. Criteria for IA and therapeutic responses were judged by an independent panel. Results: Of the 331 patients enrolled, only 225 met diagnos…

MaleAntifungal Agentsmedicine.medical_treatmentSalvage therapyHematopoietic stem cell transplantationAspergillosisGastroenterologyEchinocandinsAmphotericin BChildAged 80 and overResearch Support Non-U.S. Gov'tMiddle AgedLipoproteins [administration & dosage]Infectious DiseasesChild PreschoolAcute DiseaseCombinationDrug Therapy CombinationFemalemedicine.drugAdultMicrobiology (medical)medicine.medical_specialtyAdolescentEchinocandinLipoproteinsBiologyAntifungalPeptides CyclicArticleLipopeptidesPharmacotherapyInternal medicineAmphotericin BmedicineHumansAspergillosisEchinocandinAgedChemotherapyAspergillosis [drug therapy]MicafunginInfantmedicine.diseasebacterial infections and mycosesSurgeryPeptides Cyclic [administration & dosage]MicafunginAntifungal Agents [administration & dosage]
researchProduct

The Genotype of the Donor for the (GT)n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Do…

2015

The FOXP3 gene encodes for a protein (Foxp3) involved in the development and functional activity of regulatory T cells (CD4+/CD25+/Foxp3+), which exert regulatory and suppressive roles over the immune system. After allogeneic stem cell transplantation, regulatory T cells are known to mitigate graft versus host disease while probably maintaining a graft versus leukemia effect. Short alleles (<=(GT)(15)) for the (GT)(n) polymorphism in the promoter/enhancer of FOXP3 are associated with a higher expression of FOXP3, and hypothetically with an increase of regulatory T cell activity. This polymorphism has been related to the development of auto-or alloimmune conditions including type 1 diabetes …

MaleAnálisis de supervivenciatrasplante de células madre hematopoyéticasmedicine.medical_treatmenthumanos:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis [Medical Subject Headings]Graft vs Host Diseaselcsh:MedicinePolimorfismo genético:Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]Hematopoietic stem cell transplantationStem cellsRegiones promotoras genéticas:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Genetic Techniques::Genetic Association Studies [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Trasplante homólogoIL-2 receptorLymphocytesMasculinoPromoter Regions Geneticlcsh:Sciencemediana edadancianoMultidisciplinaryAdultoFemenino:Analytical Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures Operative::Transplantation::Cell Transplantation::Stem Cell Transplantation::Hematopoietic Stem Cell Transplantation [Medical Subject Headings]Hematopoietic Stem Cell TransplantationFOXP3Forkhead Transcription Factorsadultoanálisis de supervivenciaMiddle AgedTissue DonorsHumanosestudios de asociación genéticaadulto jovenmedicine.anatomical_structuresurgical procedures operativeCèl·lules T:Chemicals and Drugs::Amino Acids Peptides and Proteins::Proteins::Transcription Factors::Winged-Helix Transcription Factors::Forkhead Transcription Factors [Medical Subject Headings]Female:Phenomena and Processes::Genetic Phenomena::Genotype [Medical Subject Headings]Factores de transcripción en cabeza de tenedorCèl·lules mareTrasplante de células madre hematopoyéticasResearch ArticleAdult:Named Groups::Persons::Age Groups::Adult::Young Adult [Medical Subject Headings]GenotypeGraft-vs-Leukemia EffectRegulatory T cellAncianoT cells:Check Tags::Male [Medical Subject Headings]Graft vs Leukemia Effectfactores de transcripción en cabeza de tenedorHuman leukocyte antigenBiologyEnfermedad injerto contra huéspedLimfòcitsYoung AdultDonantes de tejidos:Named Groups::Persons::Tissue Donors [Medical Subject Headings]:Named Groups::Persons::Age Groups::Adult [Medical Subject Headings]medicineHumansTransplantation Homologous:Named Groups::Persons::Age Groups::Adult::Aged [Medical Subject Headings]Genetic Association StudiesAgedMediana edadTransplantationPolymorphism GeneticEstudios de asociación genéticaEfecto injerto contra leucemialcsh:Rdonantes de tejidostrasplante:Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism Genetic [Medical Subject Headings]medicine.diseaseSurvival Analysis:Diseases::Immune System Diseases::Graft vs Host Disease [Medical Subject Headings]Transplantation:Analytical Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures Operative::Transplantation::Transplantation Homologous [Medical Subject Headings]efecto injerto contra leucemiaGraft-versus-host disease:Check Tags::Female [Medical Subject Headings]Immunology:Phenomena and Processes::Immune System Phenomena::Immune System Processes::Transplantation Immunology::Graft vs Host Reaction::Graft vs Tumor Effect::Graft vs Leukemia Effect [Medical Subject Headings]enfermedad injerto contra huésped:Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Gene Components::Regulatory Elements Transcriptional::Promoter Regions Genetic [Medical Subject Headings]lcsh:QgenotipoGenotipoPLoS ONE
researchProduct

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion

2018

The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46%…

MaleBLOODDatabases FactualIMPACTCHROMOSOMECancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]medicine.medical_treatment[SDV]Life Sciences [q-bio]MedizinHematopoietic stem cell transplantationPROGNOSTIC SCORING SYSTEMGastroenterology0302 clinical medicineRecurrencehemic and lymphatic diseasesMDSCumulative incidenceLENALIDOMIDEIncidenceIncidence (epidemiology)Hazard ratioHematopoietic Stem Cell TransplantationHematologyMiddle AgedAllograftsTP53 MUTATIONSEUROPEAN-SOCIETY3. Good healthSurvival Rate030220 oncology & carcinogenesisWORKING PARTYChromosomes Human Pair 5FemaleChromosome DeletionLife Sciences & BiomedicineDEL(5Q)del (5q)medicine.drugAdultmedicine.medical_specialtyImmunology3122 CancersDisease-Free SurvivalSettore MED/01 - Statistica Medica03 medical and health sciencesSex FactorsAll institutes and research themes of the Radboud University Medical CenterInternal medicinemedicineHumansMARROW-TRANSPLANTATIONSurvival rateLenalidomideTransplantationScience & Technologybusiness.industryMyelodysplastic syndromesmedicine.diseaseAllogeneic stem cell transplantationTransplantationMyelodysplastic Syndromesbusiness030215 immunology
researchProduct